Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024
12:46pm, Friday, 29'th Sep 2023
PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.
PTC Therapeutics announces job cuts to lower annual operating expenses
05:17pm, Thursday, 28'th Sep 2023
Drugmaker PTC Therapeutics said on Thursday it plans to cut workforce, which would impact about 25% of the organization, as it aims to reduce its yearly operating expenses.
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
05:16am, Wednesday, 20'th Sep 2023
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug
02:18pm, Monday, 18'th Sep 2023
PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat
PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug
09:28am, Friday, 15'th Sep 2023
European regulators voted against fully approving a muscular dystrophy treatment from PTC Therapeutics, and PTC stock crashed Friday.
PTC Therapeutics slumps on EU snub for DMD drug
09:18am, Friday, 15'th Sep 2023
PTC Therapeutics (NASDAQ:PTCT) stock sank in Friday premarket trading after the European Medicines Agency (EMA) turned down full market authorization for Translarna, its key treatment for Duchenne mu
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
01:38pm, Friday, 25'th Aug 2023
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
PTC Therapeutics: Struggling Still But Potential Remains
08:10am, Monday, 21'st Aug 2023
PTC Therapeutics, Inc. lacks solid margins and revenue streams, increasing investment risks. The company focuses on developing medicines for rare disorders, but a failed drug test caused stock price t
PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript
12:05am, Friday, 04'th Aug 2023
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Ron Aldridge - Senior Director, Investor Relations Matthew Klein - Chief Executive
PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31pm, Thursday, 03'rd Aug 2023
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics c
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
06:46pm, Thursday, 03'rd Aug 2023
PTC Therapeutics (PTCT) came out with a quarterly loss of $2.66 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $2.13 per share a year ago.
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
12:00pm, Tuesday, 11'th Jul 2023
SOUTH PLAINFIELD, N.J., July 11, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), announced today that the company will provide a virtual presentation on PKU including discussion of the c
PTC Therapeutics Huntington's disease drug shows promise in mid-stage trial
07:33am, Wednesday, 21'st Jun 2023
PTC Therapeutics Inc said on Wednesday its experimental Huntington's disease drug lowered mutated protein levels that cause the disease, citing interim data from a mid-stage study.
PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study
01:58pm, Wednesday, 24'th May 2023
PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.
Why Is PTC Therapeutics (PTCT) Stock Down 21% Today?
09:12am, Wednesday, 24'th May 2023
PTC Therapeutics (NASDAQ: PTCT ) stock is taking a beating on Wednesday after the company provided investors with an update on a clinical trial. The bad news for PTCT stock is the company's MOVE-FA tr
